Quince Therapeutics (QNCX) Competitors $1.25 +0.05 (+4.17%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$1.25 0.00 (0.00%) As of 05:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNCX vs. KOD, NVCT, INBX, PRQR, MNPR, ELDN, ESPR, VYGR, DERM, and DMACShould you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Kodiak Sciences (KOD), Nuvectis Pharma (NVCT), Inhibrx (INBX), ProQR Therapeutics (PRQR), Monopar Therapeutics (MNPR), Eledon Pharmaceuticals (ELDN), Esperion Therapeutics (ESPR), Voyager Therapeutics (VYGR), Journey Medical (DERM), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Quince Therapeutics vs. Its Competitors Kodiak Sciences Nuvectis Pharma Inhibrx ProQR Therapeutics Monopar Therapeutics Eledon Pharmaceuticals Esperion Therapeutics Voyager Therapeutics Journey Medical DiaMedica Therapeutics Kodiak Sciences (NASDAQ:KOD) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Do insiders & institutionals have more ownership in KOD or QNCX? 89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 45.3% of Kodiak Sciences shares are held by insiders. Comparatively, 20.3% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor KOD or QNCX? Kodiak Sciences received 9 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Quince Therapeutics an outperform vote while only 26.76% of users gave Kodiak Sciences an outperform vote. CompanyUnderperformOutperformKodiak SciencesOutperform Votes1926.76% Underperform Votes5273.24% Quince TherapeuticsOutperform Votes1090.91% Underperform Votes19.09% Is KOD or QNCX more profitable? Quince Therapeutics' return on equity of -53.27% beat Kodiak Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kodiak SciencesN/A -84.52% -45.40% Quince Therapeutics N/A -53.27%-22.73% Which has stronger valuation & earnings, KOD or QNCX? Kodiak Sciences is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKodiak SciencesN/AN/A-$260.49M-$3.63-1.11Quince TherapeuticsN/AN/A-$31.39M-$1.39-0.90 Does the media prefer KOD or QNCX? In the previous week, Kodiak Sciences had 6 more articles in the media than Quince Therapeutics. MarketBeat recorded 8 mentions for Kodiak Sciences and 2 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.94 beat Kodiak Sciences' score of 0.11 indicating that Quince Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, KOD or QNCX? Kodiak Sciences has a beta of 2.27, indicating that its stock price is 127% more volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Do analysts prefer KOD or QNCX? Kodiak Sciences currently has a consensus target price of $9.00, indicating a potential upside of 123.33%. Quince Therapeutics has a consensus target price of $8.00, indicating a potential upside of 540.00%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than Kodiak Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kodiak Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 SummaryQuince Therapeutics beats Kodiak Sciences on 11 of the 16 factors compared between the two stocks. Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNCX vs. The Competition Export to ExcelMetricQuince TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.84M$3.09B$5.57B$8.63BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-1.0133.3227.1220.06Price / SalesN/A469.84412.30157.10Price / CashN/A168.6838.2534.64Price / Book0.633.457.064.70Net Income-$31.39M-$72.35M$3.23B$247.88M7 Day Performance5.04%6.23%2.86%2.63%1 Month Performance21.36%16.53%9.07%6.36%1 Year Performance74.83%-16.90%31.45%14.05% Quince Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNCXQuince Therapeutics3.7016 of 5 stars$1.25+4.2%$8.00+540.0%+58.6%$56.84MN/A-1.0160Positive NewsKODKodiak Sciences4.3268 of 5 stars$3.60+5.9%$9.00+150.0%+42.9%$189.95MN/A-0.9990Short Interest ↓NVCTNuvectis Pharma2.8033 of 5 stars$8.98-4.6%$17.00+89.3%+33.2%$187.63MN/A-7.748Positive NewsINBXInhibrx3.1086 of 5 stars$12.96-3.8%N/A-12.8%$187.61M$200K0.11166Positive NewsUpcoming EarningsPRQRProQR Therapeutics3.0445 of 5 stars$1.78+7.2%$8.00+349.4%-0.5%$187.28M$18.97M-5.56180Positive NewsAnalyst RevisionMNPRMonopar Therapeutics3.258 of 5 stars$30.01-5.4%$55.33+84.4%+750.4%$183.51MN/A-15.2310News CoveragePositive NewsELDNEledon Pharmaceuticals2.6468 of 5 stars$3.06+2.0%$12.50+308.5%+3.4%$183.24MN/A-1.5210Positive NewsESPREsperion Therapeutics4.1016 of 5 stars$0.92+8.1%$6.25+580.4%-58.3%$182.07M$259.57M-1.44200Options VolumeAnalyst RevisionVYGRVoyager Therapeutics4.4313 of 5 stars$3.29+20.1%$13.39+307.0%-61.0%$182.06M$66.96M4.63100Trending NewsAnalyst RevisionGap UpHigh Trading VolumeDERMJourney Medical2.3183 of 5 stars$7.81-3.1%$9.88+26.4%+21.7%$181.94M$56.24M-8.3190Positive NewsShort Interest ↑High Trading VolumeDMACDiaMedica Therapeutics1.3602 of 5 stars$4.17+1.5%$8.00+91.8%+54.4%$178.82MN/A-7.4520Short Interest ↑ Related Companies and Tools Related Companies Kodiak Sciences Alternatives Nuvectis Pharma Alternatives Inhibrx Alternatives ProQR Therapeutics Alternatives Monopar Therapeutics Alternatives Eledon Pharmaceuticals Alternatives Esperion Therapeutics Alternatives Voyager Therapeutics Alternatives Journey Medical Alternatives DiaMedica Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNCX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
